Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

CONCOR-1 Trial Description: A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness. This is a prospective randomized control trial that is comparing convalescent plasma to standard of care in adult patients admitted to Canadian hospitals with respiratory complications from COVID-19. Intervention will be 500 mL of convalescent plasma from donors with SAR-CoV-2 neutralizing antibodies in addition to standard of care. We are not yet enrolling patients. There will be between 40-60 sites participating across Canada.

Study team
Donald Arnold
Donald Arnold
MD
Hamilton Health Sciences Centre
Trial name Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Type of trial Phase II
Trial ID NCT 04315298
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
United States, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of severity strata. (This initiative also has pan-Canadian sites.)

Study team
Trial name Health Behavior Change During COVID-19 Pandemic
Type of trial Not Applicable
Trial ID NCT04367337
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
New Brunswick
Trial description

This observational study aims at testing the adherence to handwashing guidelines (the World Health Organization, WHO, 2020) at two measurement points, spanning 1 month. Adults from the general population in 14 countries (Poland, Australia, Canada, China, France, Gambia, Germany, Israel, Italy, Malaysia, Portugal, Romania, Singapore, Switzerland) will provide self-report data on handwashing behavior and its social-cognitive predictors (perceived effectiveness of handwashing, risk perception, outcome expectancy, self-efficacy, intention, planning, and action control), anxiety, as well as COVID-19 morbidity and mortality rates within the country.

Study team
Dombrowski
Dr. Stephan Dombrowski
PhD
University of New Brunswick
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Yukon, Northwest Territories, Nunavut
Trial description

This study is an adaptive, randomized, open-label, controlled clinical trial.Subjects will be randomized to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first

Study team
Nelson Lee
Nelson Lee
MD
University of Alberta Hospital
Allison Mah
Allison Mah
MD
Vancouver General Hospital,
Natasha Press
Natasha Press
MD
St Paul’s Hospital
Shane English
Shane English
MD
The Ottawa Hospital
Robert Fowler
Robert Fowler
MD
Sunnybrook Health Sciences Centre
Bryan Coburn
Bryan Coburn
MD
Toronto Western Hospital
Matthew Cheng
Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Alexis Turgeon
Alexis Turgeon
MD
CHU de Québec – Université LavalRecruiting
Francois Lellouche
Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université LavalRecruiting
Francois Lamontagne
Francois Lamontagne
MD, FRCPC, MSc
Université de Sherbrooke and CIUSSS de l’Estrie – CHUS